Sofituzumab vedotin

DB15349InvestigationalProtein Based Therapies

Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).

Mechanism: Pharmacologically active on Mucin-16
Curator reviewed
Also known as: DMUC5754A

Resolves to

Compound

UNII2X3CKG601LCAS1418200-58-4

Targets

Q8WXI7MUC16

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sofituzumab vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account